Recent Company News

• 04:01 AM ET Feb 25, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (138 total)

• 01:05 AM ET Feb 25, 2026
  

  Sandoz Group reports FY core EPS $3.64 vs FactSet $3.40 [17 est, $3.02-4.20]; hikes divi by 33% and guides FY26 (CHF 65.64, 0.00)

• 09:21 PM ET Feb 24, 2026
  

  NICE recommends Genentech's Avastin (and biosimilars) with fluoropyrimidine-based chemotherapy to treat metastatic colorectal cancer (CHF 374.00, 0.00)

• 05:01 AM ET Feb 23, 2026
  

  Sandoz confirms European Commission approval for Ranluspec (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology (CHF 65.90, -1.14)

• 04:23 AM ET Feb 20, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (104 total)

• 03:53 AM ET Feb 19, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (123 total)

• 01:01 AM ET Feb 18, 2026
  

  Sandoz receives US FDA approval to expand Enzeevu (aflibercept-abzv) label for multiple retinal indications (CHF 67.16, 0.00)

• 04:36 AM ET Feb 12, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 04:14 AM ET Feb 12, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (208 total)

• 02:09 AM ET Feb 12, 2026
  

  Sandoz Group upgraded to buy from hold at Jefferies (CHF 62.72, 0.00)